Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Chen N, Liu S, Qin D, Guan D, Chen Y, Hou C, Zheng S, Wang L, Chen X, Chen W, Zhang L. Fate tracking reveals differences between Reelin⁺ hepatic stellate cells (HSCs) and Desmin⁺ HSCs in activation, migration and proliferation. Cell Prolif 2023;56:e13500. [PMID: 37246473 PMCID: PMC10693182 DOI: 10.1111/cpr.13500] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2023] [Revised: 04/20/2023] [Accepted: 05/02/2023] [Indexed: 05/30/2023] Open

For:	Chen N, Liu S, Qin D, Guan D, Chen Y, Hou C, Zheng S, Wang L, Chen X, Chen W, Zhang L. Fate tracking reveals differences between Reelin⁺ hepatic stellate cells (HSCs) and Desmin⁺ HSCs in activation, migration and proliferation. Cell Prolif 2023;56:e13500. [PMID: 37246473 PMCID: PMC10693182 DOI: 10.1111/cpr.13500] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2023] [Revised: 04/20/2023] [Accepted: 05/02/2023] [Indexed: 05/30/2023] Open

Number

Cited by Other Article(s)

Kim HY, Rosenthal SB, Liu X, Miciano C, Hou X, Miller M, Buchanan J, Poirion OB, Chilin-Fuentes D, Han C, Housseini M, Carvalho-Gontijo Weber R, Sakane S, Lee W, Zhao H, Diggle K, Preissl S, Glass CK, Ren B, Wang A, Brenner DA, Kisseleva T. Multi-modal analysis of human hepatic stellate cells identifies novel therapeutic targets for metabolic dysfunction-associated steatotic liver disease. J Hepatol 2024:S0168-8278(24)02667-9. [PMID: 39522884 DOI: 10.1016/j.jhep.2024.10.044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/02/2024] [Revised: 10/09/2024] [Accepted: 10/29/2024] [Indexed: 11/16/2024]

Abstract

BACKGROUND & AIMS

Metabolic dysfunction-associated steatotic liver disease ranges from metabolic dysfunction-associated steatotic liver (MASL) to metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis. Transdifferentiation of hepatic stellate cells (HSCs) into fibrogenic myofibroblasts plays a critical role in the pathogenesis of MASH liver fibrosis. We compared transcriptome and chromatin accessibility of human HSCs from NORMAL, MASL, and MASH livers at single-cell resolution. We aimed to identify genes that are upregulated in activated HSCs and to determine which of these genes are key in the pathogenesis of MASH fibrosis.

METHODS

Eighteen human livers were profiled using single-nucleus (sn)RNA-seq and snATAC-seq. High priority targets were identified, then tested in 2D human HSC cultures, 3D human liver spheroids, and HSC-specific gene knockout mice.

RESULTS

MASH-enriched activated HSC subclusters are the major source of extracellular matrix proteins. We identified a set of concurrently upregulated and more accessible core genes (GAS7, SPON1, SERPINE1, LTBP2, KLF9, EFEMP1) that drive activation of HSCs. Expression of these genes was regulated via crosstalk between lineage-specific (JUNB/AP1), cluster-specific (RUNX1/2) and signal-specific (FOXA1/2) transcription factors. The pathological relevance of the selected targets, such as SERPINE1 (PAI-1), was demonstrated using dsiRNA-based HSC-specific gene knockdown or pharmacological inhibition of PAI-1 in 3D human MASH liver spheroids, and HSC-specific Serpine1 knockout mice.

CONCLUSION

This study identified novel gene targets and regulatory mechanisms underlying activation of MASH fibrogenic HSCs and demonstrated that genetic or pharmacological inhibition of select genes suppressed liver fibrosis.

IMPACT AND IMPLICATIONS

Herein, we present the results of a multi-modal sequencing analysis of human hepatic stellate cells (HSCs) from NORMAL, MASL (metabolic dysfunction-associated steatotic liver), and metabolic dysfunction-associated steatohepatitis (MASH) livers. We identified additional subclusters that were not detected by previous studies and characterized the mechanism by which HSCs are activated in MASH livers, including the transcriptional machinery that induces the transdifferentiation of HSCs into myofibroblasts. For the first time, we described the pathogenic role of activated HSC-derived PAI-1 (a product of the SERPINE1 gene) in the development of MASH liver fibrosis. Targeting the RUNX1/2-SERPINE1 axis could be a novel strategy for the treatment of liver fibrosis in patients.

Collapse

Affiliation(s)

Hyun Young Kim Department of Medicine, University of California San Diego, La Jolla, California, USA; Department of Surgery, University of California San Diego, La Jolla, California, USA
Sara Brin Rosenthal Center for Computational Biology and Bioinformatics, University of California San Diego, La Jolla, California, USA
Xiao Liu Department of Medicine, University of California San Diego, La Jolla, California, USA; Department of Surgery, University of California San Diego, La Jolla, California, USA
Charlene Miciano Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, California, USA; Center for Epigenomics, University of California San Diego, La Jolla, California, USA
Xiaomeng Hou Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, California, USA; Center for Epigenomics, University of California San Diego, La Jolla, California, USA
Michael Miller Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, California, USA; Center for Epigenomics, University of California San Diego, La Jolla, California, USA
Justin Buchanan Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, California, USA; Center for Epigenomics, University of California San Diego, La Jolla, California, USA
Olivier B Poirion Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, California, USA; Center for Epigenomics, University of California San Diego, La Jolla, California, USA
Daisy Chilin-Fuentes Department of Medicine, University of California San Diego, La Jolla, California, USA
Cuijuan Han Department of Medicine, University of California San Diego, La Jolla, California, USA
Mojgan Housseini Department of Pathology, University of California San Diego, La Jolla, California, USA
Raquel Carvalho-Gontijo Weber Department of Medicine, University of California San Diego, La Jolla, California, USA; Department of Surgery, University of California San Diego, La Jolla, California, USA
Sadatsugu Sakane Department of Medicine, University of California San Diego, La Jolla, California, USA; Department of Surgery, University of California San Diego, La Jolla, California, USA
Wonseok Lee Department of Medicine, University of California San Diego, La Jolla, California, USA; Department of Surgery, University of California San Diego, La Jolla, California, USA
Huayi Zhao Department of Medicine, University of California San Diego, La Jolla, California, USA; Department of Surgery, University of California San Diego, La Jolla, California, USA
Karin Diggle Department of Medicine, University of California San Diego, La Jolla, California, USA
Sebastian Preissl Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, California, USA; Center for Epigenomics, University of California San Diego, La Jolla, California, USA; Institute of Experimental and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Freiburg, Freiburg, Germany
Christopher K Glass Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, California, USA
Bing Ren Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, California, USA; Center for Epigenomics, University of California San Diego, La Jolla, California, USA
Allen Wang Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, California, USA; Center for Epigenomics, University of California San Diego, La Jolla, California, USA.
David A Brenner Department of Medicine, University of California San Diego, La Jolla, California, USA; Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA.
Tatiana Kisseleva Department of Surgery, University of California San Diego, La Jolla, California, USA.

Collapse

Siqueira JS, Garcia JL, Ferron AJT, Moreto F, Sormani LE, Costa MR, Palacio TLN, Nai GA, Aldini G, Francisqueti-Ferron FV, Correa CR, D'Amato A. Proteomic study of gamma-oryzanol preventive effect on a diet-induced non-alcoholic fatty liver disease model. J Nutr Biochem 2024;127:109607. [PMID: 38432453 DOI: 10.1016/j.jnutbio.2024.109607] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2023] [Revised: 02/11/2024] [Accepted: 02/27/2024] [Indexed: 03/05/2024]